This bill amends section 9002 of the Farm Security and Rural Investment Act of 2002 to accelerate federal demand for biobased products and to steer more of that demand toward goods produced in the United States. It directs changes to procurement rules, reporting, and program priorities so agencies systematically increase biobased-only contracts or purchase volumes year over year, adopt price preferences for qualifying biobased goods, and publish information about compliance and barriers.
Why it matters: the federal government is a major purchaser; changing how agencies buy industrial supplies, cleaning products, and materials can create predictable demand for domestic biomanufacturing, affect supply chains for commodity and specialty feedstocks, and impose new compliance and data-reporting tasks on procurement offices and contractors. The bill couples market-pull measures with administrative steps—training, catalog updates, centralized data verification, and a GAO review—to translate preference language into operational practice.
At a Glance
What It Does
Modifies the USDA Biobased Markets Program to require procuring agencies to increase biobased-only contracts or volumes annually, add price preferences, and prioritize products produced wholly or partly in the U.S.; it also expands required reporting and oversight.
Who It Affects
Federal procuring agencies and their contracting officers; GSA (catalogs and procurement data systems); manufacturers and biorefineries supplying biobased products; contractors that rely on imported feedstocks or finished biobased goods.
Why It Matters
This shifts federal demand dynamics toward domestically produced biobased goods and creates compliance workstreams (training, reporting, verification). For industry, it creates a procurement signal that can justify investment in U.S. biomanufacturing capacity; for procurement shops, it creates new operational requirements and monitoring obligations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites how the federal government identifies, buys, and tracks biobased products under the USDA’s biobased markets program. It adds a mandate that agencies must ‘‘update the procurement requirement on an annual basis’’ by increasing either the number of contracts that are limited to biobased products or the volume purchased under those contracts compared with the prior year.
That is a directional, repeatable metric rather than a fixed percentage target; agencies will need internal processes to measure and document year-over-year increases.
The text also erects two procurement filters: agencies may treat items as exempt when the only available biobased options exceed a statutory price preference, or when an item would not meet Buy American requirements. At the same time, the bill explicitly instructs the program to promote biobased products ‘‘produced wholly or in part in the United States’’ and to establish price preferences for qualifying items—giving agencies an explicit statutory reason to favor domestic suppliers when awarding contracts.On administration and oversight, the bill layers practical implementation steps.
Agencies must publicly report prescribed data to Congress and post it online, including explanations when they fail to meet procurement requirements and categories where biobased options are commercially unavailable. Congress is required to publish guidance and identify barriers; contracting personnel (contracting officers, purchase card managers and holders) must complete training and begin implementation within two years.
The GSA must update federal catalogs and procurement data systems within two years to mark eligible biobased products, and the Office of Federal Procurement Policy must annually collect and publicly release the agency reports and verify agency compliance using those reports.Finally, the bill changes the program’s performance metrics (adding measures such as the geographic distribution and economic value of biomanufacturing facilities) and orders the Comptroller General to complete a two‑year review assessing agency compliance, the usefulness of collected data, and opportunities to strengthen procurement of domestic biobased products. Those review and metric changes create the informational basis for future rulemaking or statutory adjustments.
The Five Things You Need to Know
The bill requires procuring agencies to update their procurement requirement annually by increasing either the number of biobased-only contracts or the volume purchased from the previous year.
It authorizes and directs the program to establish price preferences for qualifying biobased products and to explicitly promote products produced wholly or partially in the United States.
Within 2 years, agencies must ensure contracting officers, purchase card managers, card holders, and other relevant staff complete training and begin implementing biobased purchasing obligations.
GSA must update federal catalogs and procurement data systems within 2 years to clearly mark eligible biobased products, improving visibility in contract solicitation and ordering systems.
The Comptroller General must report to Congress within 2 years on implementation, including agency compliance, data adequacy, and recommendations to improve procurement of biobased products made in the U.S.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Annual procurement ramp-up requirement
This amendment forces agencies to treat biobased procurement as a moving target: each year the agency must show an increase in either the number of contracts restricted to biobased products or the total volume purchased under those contracts relative to the prior year. Practically, that creates a recordkeeping requirement (baseline year, annual comparison) and requires agencies to choose which metric—count of contracts or volume—is their control lever. Agencies will need to define the scope of ‘‘biobased-only’’ contracts and set internal processes to reconcile contract awards with purchase data.
Exclusions tied to price preference and Buy American
The bill adds explicit language allowing agencies to treat items as unavailable or exempt if the only biobased options exceed the established price preference or if the items would not meet Buy American statutes (chapter 83 of title 41). That creates a two-way gate: price sensitivity can justify non‑purchase of biobased goods, but so can conflicts with existing domestic sourcing rules. Contracting officers will need to document price comparisons and Buy American compliance analyses when using these exclusions.
Program priorities: favor U.S.-produced products and introduce price preferences
The program’s guidance list is expanded to include promotion of biobased products produced wholly or in part in the U.S., and an express authorization to set price preferences. That gives program managers a statutory basis to write guidance, templates, or scoring rules that award extra consideration (or price adjustments) to domestic suppliers. The statutory text does not prescribe the size of the preference, leaving rulemakers or implementing agencies to set concrete rates and thresholds.
New reporting format, training deadline, catalog updates, and centralized verification
Agencies must publish required reports online and include specific items: explanations when they miss procurement targets, categories where no commercial biobased substitute exists, and other data points. The bill imposes a 2‑year deadline for training contracting personnel and for GSA to mark eligible biobased products in federal catalogs and procurement systems. It also makes OFPP responsible for annual collection of agency reports and for verifying agency compliance based on those reports—creating a centralized compliance and transparency regime tied to existing federal procurement oversight structures.
Encouraging domestic production within program objectives
A targeted edit instructs the program to ‘‘encourage the purchase of biobased products that are produced wholly or in part within the United States.’' That language shifts the program’s objectives from neutral market recognition toward an explicit industrial policy orientation: procurement becomes a lever for domestic manufacturing, not just environmental labeling or market development.
GAO review and recommendations
The bill adds a Comptroller General review due within 2 years assessing: agency compliance with the procurement requirement, the effectiveness of program guidance, compliance with new reporting and training rules, the recognition programs, and whether the collected data is adequate to guide policy. The GAO deliverable must give lawmakers a factual basis for tightening, relaxing, or amending the program, and it specifically asks for recommendations to improve procurement of biobased products made in the U.S.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Domestic biomanufacturers and biorefineries: the statutory push for U.S.-produced biobased products and creation of price preferences increases federal demand certainty and can justify expansion or new investment in domestic production capacity.
- U.S. agricultural producers and feedstock suppliers: higher federal demand for biobased products can translate into more market outlets for agricultural feedstocks and higher estimated economic return that the program will now measure.
- Procurement transparency advocates and sustainability offices: required public reporting and OFPP verification create a clearer data trail for measuring program performance and holding agencies accountable.
- Rural economies and manufacturing hubs: the bill’s emphasis on geographic distribution of biomanufacturing facilities directs attention and potential future resources toward regional industrial development tied to biobased supply chains.
Who Bears the Cost
- Federal procuring agencies and contracting offices: they must document baselines, implement annual increases, run trainings, prepare public reports, and cooperate with OFPP verification—work that will require staff time and potentially new IT changes.
- GSA and procurement system administrators: GSA must update catalogs and data systems to flag eligible biobased products, a nontrivial systems and taxonomy project with upfront programming and maintenance costs.
- Contractors and suppliers relying on imported feedstocks or foreign-made products: price preferences and an explicit preference for U.S.-produced goods will disadvantage some incumbent suppliers and may require them to retool sourcing or domesticate production.
- Small manufacturers and suppliers: certification, documentation, and meeting domestic-content expectations can impose compliance costs that disproportionately affect small businesses unless implementation includes proportionality measures.
Key Issues
The Core Tension
The central dilemma is between using federal procurement as an industrial policy tool to accelerate U.S. biomanufacturing and preserving procurement efficiency and competition: favoring domestic biobased goods can spur investment and jobs, but it can also raise costs, complicate compliance, and create supply constraints that undermine the very procurement objectives the bill intends to meet.
The bill blends procurement preference with operational controls, but it leaves important design choices to agencies and implementing guidance. Key open questions include how agencies will define and measure ‘‘produced wholly or in part in the United States’’ for complex supply chains, how large a price preference will be (and whether it will be fixed or tiered), and what documentation will satisfy verification.
Those choices determine whether the policy nudges supply chains toward domestic sourcing or simply adds paperwork without materially shifting procurement outcomes.
Another tension is between the bill’s market-pull ambitions and procurement realities. Requiring annual increases in biobased purchases without matching investments in supply expansion risks agencies repeatedly invoking price or availability exceptions.
The verification role assigned to OFPP rests on agency self-reported data, which raises concerns about data quality, inconsistent reporting formats across agencies, and potential gaming unless OFPP and GSA build robust validation processes. Finally, promoting U.S.-produced goods while relying on price preferences interacts unevenly with existing Buy American rules and with trade obligations; the statute allows Buy American to be a valid exclusion, but does not reconcile how overlapping domestic-preference regimes will be prioritized in practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.